Publication:
A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema.

No Thumbnail Available

Date

2021-02-23

Authors

Doña, Inmaculada
Torres, Maria Jose

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

John Wiley and Sons
Metrics
Google Scholar
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Hereditary angioedema (HAE) is a rare inherited chronic disease characterized by unpredictable recurrent attacks of cutaneous and submucosal swelling potentially involving airways, frequently upper ones, and compromising patient's life. This implies a serious health problem with significant disease burden and reduced life quality. This disease presents a great clinical variability and different endotypes, hampering diagnosis and requiring a personalized treatment. The primary mediator of swelling in most phenotypes is bradykinin, which increases vasodilation and vascular permeability by binding to the bradykinin B2 receptor.

Description

MeSH Terms

Angioedemas, Hereditary
Antibodies, Monoclonal, Humanized
Complement C1 Inhibitor Protein
Humans
Plasma Kallikrein

DeCS Terms

Angioedemas hereditarios
Costo de enfermedad
Enfermedad crónica
Vasodilatación
Bradiquinina
Permeabilidad capilar

CIE Terms

Keywords

Vasodilation, Chronic Disease, Angioedemas, Hereditary, Quality of Life, Bradykinin, Cost of Illness, Capillary Permeability, Andalusian Center for Nanomedicine and Biotechnology-BIONAND

Citation

Doña I, Torres MJ. A new oral kallikrein inhibitor for long-term prophylaxis of hereditary angioedema. Allergy. 2021 Jun;76(6):1619-1620